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Abstract
Background: Human epidermal growth factor receptor 2 (HER2) is as a target gene for trastuzumab in patients
with breast cancer. Accurate determination of HER2 status and strict quality control are necessary to ensure
reproducibility and accuracy of the techniques used for the determination of HER2 status.
Methods: We used three different types of samples: formalin-fixed and paraffin-embedded (FFPE) samples prepared
from cell lines, agarose gel samples using cell lines, and xenograft tumor samples. One cell line for FFPE or
xenografts did not overexpress HER2, while the others showed different levels of HER2 overexpression. We
compared the morphology, HER2 gene amplification status, and HER2 protein expression status of these samples
with those of clinical specimens.
Results: We successfully produced three kinds of samples for quality control. Cells from the cell line-sample
sections were dispersed while those from the agarose gel-sample sections and xenograft tumor sample sections
(prepared from the both cell lines) were concentrated in one area. The FISH results for all three kinds of samples
were as expected. The IHC results of the cell line samples and xenograft tumor samples were as expected, but the
staining level of the agarose gel samples, using HER2-overexpressed cell lines was weak which might be regarded
as a false negative result.
Conclusions: Xenograft tumor samples might be used as an additional option for quality control in FISH and IHC.
However, it might not replace the clinical specimen quality controls directly.
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Background
Approximately 25 % of patients with invasive breast can-
cer overexpress human epidermal growth factor receptor
2 (HER2) [1]. HER2 overexpression, mainly because of
HER2 amplification, is significantly associated with aggres-
sive disease and poor prognosis [2]. Trastuzumab can bind
the extracellular domain of HER2, and has a remarkable
impact on the treatment of patients with HER2-positive
breast by several pathways [3–5]. Therefore, trastuzumab
was approved by the United States (US) Food and Drug
Administration (FDA) for the treatment of breast cancer.
Hence, accurate determination of the HER2 status in pa-
tients with breast cancer is crucial [6].
Immunohistochemistry (IHC), for measuring protein
overexpression, and fluorescence in situ hybridization
(FISH), for measuring HER2 amplification, are the most
commonly applied methods for the assessment of HER2
status [7]. Although both these methods can be applied
to evaluate protein overexpression and gene amplifica-
tion in relation to the morphological features of tumors,
there is large inter-laboratory variation in the procedure,
staff, and interpretation, which affects the analytical sen-
sitivity and specificity of these assays, especially in the
case of indeterminate samples [8].
Ensuring the accuracy and reproducibility of HER2 de-
tection by IHC and FISH testing is a fundamental pre-
requisite for targeted therapy. Recommendations for
HER2 testing were developed by the American Society
of Clinical Oncology (ASCO) and the College of Ameri-
can Pathologists (CAP) in 2007 and were updated in
2013 [9, 10] to improve the performance of these tests.
HER2 detection requires precisely characterized and uni-
versally available reference controls [11]. Adequate qual-
ity control is necessary to diminish inter-laboratory
variation and external quality assurance.
Recently, a consensus was reached to create clinical
specimen or cell line controls as reference materials for
HER2 testing [12]. Quality control of clinical specimens
facilitates the assessment of variation in methodologies
and laboratories. However, some disadvantages have lim-
ited the development of these quality controls, such as
production and ethics. Therefore, we developed new
xenograft tumor controls and checked their suitability
for internal quality control (IQC) and external quality
assurance (EQA). In this study, we compared three qual-
ity control samples with traditional clinical specimens.
The aim of our study was to identify the most appropri-
ate quality control that would ensure maximum accur-
acy and reproducibility of IHC and FISH.
Methods
Cell lines
The breast cancer cell lines MCF-7, MDA-MB-453,
BT474, and SKBR-3 were obtained from the Cell Based
Medical Center of Basic Medicine of Peking Union Med-
ical College (Beijing, China). Cells were cultured as rec-
ommended by the suppliers. The HER2 status of the cell
lines has been reported in previous studies [1, 13].
MDA-MB-453, BT474, and SKBR-3 expressed HER2,
while MCF-7 did not. All four cell lines were applied for
the preparation of three quality-control samples as de-
scribed below.
Samples
Two surgical specimen cases of invasive breast cancer
with of known HER2 status were selected and obtained
from the Pathology Department of Beijing Hospital,
Beijing, China. Our protocol and specimen were ap-
proved by the Ethics Committee of the National Center
for Clinical Laboratories. One of the samples tested
negative for HER2 (A2; FISH result: negative; IHC
score: 0), whereas the other sample tested positive (A12;
FISH result: positive; IHC score: 3+). The HER2 status of
these two samples was evaluated together with our pre-
pared samples.
Preparation of formalin-fixed and paraffin-embedded
(FFPE) cell line samples
Approximately 1 × 107–2 × 107 cells were obtained and
fixed in 10 % neutral-buffered formalin for approxi-
mately 2 h at room temperature. Subsequently, cell
pellets were processed with gradient ethanol for dehy-
dration and with xylene for transparency. Cell pellets were
treated with melted liquid paraffin in small Eppendorf
tubes and waxed thoroughly for 10 min; liquid paraffin
was mixed with the cell pellets, using pipette tips. The so-
lution was then chilled to achieve solidification, and the
resulting blocks were embedded in paraffin, using a stand-
ard histochemical apparatus. Hematoxylin-eosin (HE)
staining was performed to preserve the representative
morphology of each sample and the number of cells to as-
sess the uniformity of cellular distribution for each sec-
tion. Each section was 5 μm in thickness. The sections
were mounted onto slides and dried in an oven at 70 °C
for approximately 3 h to ensure maximum adhesion.
Preparation of FFPE agarose gel samples
Approximately 1 × 106-2 × 106 cells were fixed overnight
in 10 % neutral-buffered formalin at 4 °C, with the fixed
cells being allowed to sediment at the base of a 15-mL
tube with a conical base after centrifugation at 0.4 × g for
10 min, following which the formalin supernatant was re-
moved. The cells were resuspended in phosphate buffered
saline (PBS) solution, and the suspension was transferred
to 1.5-mL Eppendorf tubes and allowed to sediment again
after centrifugation at 0.4 × g for 10 min. The supernatant
was removed, leaving the cells in 10–50 μL of PBS, in
which the cells were resuspended. The cell suspension
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was embedded in prewarmed and equilibrated 3 % PBS-
buffered agarose gel in 5-mm diameter × 5-mm deep iron
molds from which small agarose-cell mixture cylinders
were extruded after the agarose was sufficiently chilled.
The agarose gel cylinders were then placed in a standard
tissue-processing cassette and processed with paraffin
wax. HE staining was performed; each section was 5 μm
in thickness.
Preparation of FFPE xenograft tumor samples
Female severe combined immunodeficient (SCID) mice
between 21 and 28 days of age (Vital River, Beijing,
China) were used; the mice were quarantined for at least
3 days prior to the study. The mice were anesthetized
with vaporized isoflurane, and suspensions of cells (all
the four cell lines, approximately 1 × 107 cells) mixed
with Matrigel™ basement membrane matrix (Corning,
New York, USA) were injected subcutaneously under
sterile conditions into the backs of mice, using a 5-gauge
needle. Once the size of the xenograft tumor had pro-
gressed to approximately 500 mm3, the mice were eu-
thanized via cervical dislocation, and all xenograft
tumors belonging to different cell lines were removed
surgically. All animal experiments were performed in
compliance with the guidelines specified by the Institute
for Experimental Animals, Beijing Hospital. Following
surgical removal of xenograft tumors from the SCID
mice, the tumors were cut into multiple pieces of ap-
proximately 250 mm3, placed into appropriately labeled
disposable plastic tissue cassettes, and then immediately
fixed in 10 % neutral-buffered formalin at 4 °C overnight.
Subsequently, automated tissue embedding was per-
formed using a Renaissance Tissue Processor (Ventana
Medical Systems, US). This included washing in a graded
ethanol series for dehydration followed by xylene washes
for transparency, and heated paraffin washes prior to em-
bedding in paraffin. HE staining was performed to ensure
that the representative morphology of each sample was
maintained. Each section was cut to a thickness of 5 μm.
Evaluation of HER2 status by FISH
FISH assays were performed following the manufacturers’
instructions (PathVysion HER-2 DNA Probe Kit, Abbott,
Chicago, IL, USA). In brief, deparaffinization, heat pre-
treatment, and protease treatment were performed se-
quentially for all the FFPE samples. After pretreatment,
the sample sections and probes were co-denatured and
hybridized. A post-hybridization wash was performed for
all sample sections in the dark using the wash buffer sup-
plied by the manufacturer. 4′,6-Diamidine-2′-phenylin-
dole dihydrochloride (DAPI) counter-stain was applied
to the target area of the sections, and fluorescence
microscopy was performed to view areas of positive
hybridization. The results were evaluated qualitatively
based on the kit recommendations.
Evaluation of HER2 expression by IHC analysis
The HER2 protein expression status of the sample slides
was assessed using a commercial primary antibody
(PATHWAY® anti-HER-2/neu (4B5) Rabbit Monoclonal
Primary Antibody; Ventana, Tucson, AZ, USA), as per
manufacturer’s instructions. Briefly, all the sample slides
were processed according to a standard tissue-processing
process, including deparaffinization, rehydration and anti-
gen retrieval. After cooling for 15 min, IHC reactions were
manually performed manually using the primary mono-
clonal antibody, 2-step plus® Poly-HRP Anti Mouse/Rabbit
IgG Detection System (ZSGB-BIO, Beijing, China) and di-
aminobenzidine (DAB) staining. HER2 protein expressed
on the membrane of tumor cells was scored as 0+, 1+, 2+,
or 3+ as recommended [10].
Results
Characteristics of the three types of samples for quality
control
In this study, we successfully developed three types of
samples that may be used for quality control in the de-
termination of HER2 status. The morphological features
of these samples in comparison with those of clinical
specimens are shown in Fig. 1. In brief, the target cells
in the cell line samples were well dispersed, but cells
embedded in the agarose gel samples were concentrated
in one area. However, the xenograft tumor samples were
similar to tumor tissue samples derived from patients
with breast cancer. Nests of carcinoma were found in
both the xenograft tumor samples and clinical speci-
mens. However, some distinctions were also found in
the samples. In the clinical specimens, a sizeable number
of normal cells was found, and the tissue structure was
complicated. Apart from the nests of carcinoma, breast
catheter and breast glands were observed. Inflammatory
cell infiltration was evident around the nests of carcin-
oma. In the xenograft tumor samples, almost all the cells
were tumor cells, and the tissue structure was simple.
Apart from the target tumor cells, only red blood cells,
fibroblast cells, and vascular endothelial cells were de-
tected. The other characteristics of the samples, as well
as the technology used and costs are shown in Table 1.
Evaluation of HER2 status by FISH
All samples prepared using the MCF-7 cell line did not
show HER2 amplification. All samples prepared MDA-
MB-453, BT474, and SKBR-3 showed positive results,
and samples using BT474 and SKBR-3 showed highly
positive results, with a cluster of positive signals (Table 2
and Additional file 1). Among the clinical specimens
(Table 2 and Fig. 2), A2 was negative and A12 was highly
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positive for HER2 amplification. Together, these results
suggested that all the samples could be applied for qual-
ity control in FISH assays.
Evaluation of HER2 expression by IHC analysis
A comparison of HER2 expression between the samples
developed by us and the clinical specimens is shown in
Table 2 and Fig. 3. Cell line samples and xenograft
tumor samples prepared from SKBR-3, BT474, and
MDA-MB-453 showed overexpression of HER2 protein
localized to the cell membrane (IHC score: 3+) relative
to samples prepared using MCF-7 (lower expression;
IHC score: 0) and the negative clinical sample (A2). In
addition, cell line samples and xenograft tumor samples
using SKBR-3 and BT474 expressed higher levels of
HER2 than samples prepared using MDA-MB-453 and
the positive clinical sample (A12). There was no differ-
ence of staining between the cell line samples and their
corresponding xenograft tumor samples. However, agar-
ose gel samples prepared using MCF-7, MDA-MB-453,
and SKBR-3 showed negative results, and the HER2 ex-
pression in agarose gel samples prepared using BT474
was lower than that in the cell line samples and xeno-
graft tumor samples prepared using BT474. The de-
tailed IHC staining scores are shown in Table 2 and
Additional file 2.
Discussion
Quality controls are required in HER2 status detection
to ensure the accuracy and reproducibility of testing [2,
10] and hence, choosing a suitable quality control is ne-
cessary for FISH and IHC assays. Currently, the best
quality controls for HER2 testing are tissue-based con-
trols from clinical specimens exhibiting both HER2 over-
expression and HER2 amplification that have been
confirmed by IHC and FISH [2]. Some studies have also
reported that cell line samples can be used for EQA as
additional quality controls instead of traditional quality
controls derived from patient tumor tissue [13, 14]. In
this study, we have developed three quality controls and
compared them with cell line samples and clinical speci-
mens to identify a suitable quality control for FISH and
IHC assays.
Different quality controls possess characteristic advan-
tages and disadvantages. At present, tissue microarray
(TMA)-based or FFPE-based quality controls prepared
from clinical specimens are widely used for EQA or IQC
in IHC or FISH testing [15, 16]. The protocol utilizing
Fig. 1 The HE staining results of three kinds of samples compared
with clinical specimen. a is section of cell lines sample; b is section
of agarose gel within cell lines sample; c is section of xenograft
tumor sample. All these sections were derived from cell lines of
MCF-7. d is section of clinical specimen (A2)
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clinical specimen quality controls is robust, cost-
effective, and rapid. Moreover, it allows continuous
monitoring of the performance of FISH and IHC testing
[16]. However, some potential limitations of clinical spe-
cimen quality controls should be considered. Since, EQA
requires a larger number of quality controls, a collection
of large clinical specimens from different patients with
breast cancer is needed. Previous studies have reported
that the properties of the samples being tested may in-
fluence the results and create bias in the comparison
[17]. Thus, heterogeneity among clinical specimens from
different patients may affect the reproducibility of assays.
Moreover, mass production of clinical specimens is diffi-
cult, and ethical problems should be taken into consider-
ation. As additional quality controls, cell line quality
controls are currently applied for IQC and EQA instead
of traditional clinical specimens. Compared with trad-
itional paraffin blocks of tumor tissues, large amounts of
such controls can be obtained easily, and the reproducibil-
ity allos for sensitive detection and decreases analytical
errors [11]. In our study, we found that cell line samples
can be applied for both IHC and FISH, as reported by pre-
vious studies [11, 18], and that the protein and gene status
of different cell lines can be determined accurately.
However, we found two main disadvantages in the use
of cell line quality controls. First, the tumor cells showed
diffuse distribution in the entire section, and the diffused
cells were difficult to observe and count. The diffused
cells were also prone to drop off for lack of tissue struc-
ture. Second, cultured cells were prone to polysomy,
which is uncommon in patient tumor tissue. This polys-
omy might affect the reproducibility of cell line quality
controls [19].
To resolve these issues, agarose gel samples prepared
using different cell lines were produced to optimize the
basic cell line samples. Embedding in agarose gel helped
gather the cells and increase the viscosity of the speci-
men. However, the morphological features of actual hu-
man tumors could not be simulated. Furthermore, we
found that the agarose gel samples could only be applied
Table 1 The characteristic of three samples for quality control
Quality control samples Cell lines samples Agarose gel samples Xenograft tumor samples Clinical specimens





with simple tissue structure
Concentrated distribution with
complicated tissue structure
Target cells count in each section >104 >103 Countless >102
Adhesion characteristic Bad Good Good Bad
Production process Easy Easy Difficult Difficult
Production period 1 month 1 month 3–4 months About 2–4 months [15]
Production cost (£/sample on
one section)
2.03 2.07 2.22 About 10 [15]
Table 2 The results of FISH and IHC method to evaluate three samples made of different cell lines for quality control
Quality control samples Cell lines’ name or
patient’s code
The results of FISH detection The results of IHC detection




Qualitative results IHC scoring
Cell lines samples MCF-7 Negative 1.15 3.05 Negative 0
MDA-MB-453 Positive 2.26 6.9 Positive 3+
SKBR-3 Positive Clusters Clusters Positive 3+
BT474 Positive Clusters Clusters Positive 3+
Agarose gel samples MCF-7 Negative 1.18 3.85 Negative 0
MDA-MB-453 Positive 2.15 7.1 Negative 0
SKBR-3 Positive Clusters Clusters Negative 1+
BT474 Positive Clusters Clusters Positive 2+
Xenograft tumor samples MCF-7 Negative 1.27 5.25 Negative 0
MDA-MB-453 Positive 2.42 8 Positive 2+
SKBR-3 Positive Clusters Clusters Positive 3+
BT474 Positive Clusters Clusters Positive 3+
Clinical specimens A2 Negative 1.07 4.07 Negative 0
A12 Positive Clusters Clusters Positive 3+
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for FISH. The use of an overheated agarose gel led to
changes in the morphology of cells. Additionally, the use
of agarose gel affected the positive results because of
weak or faded staining. The probable reason for this is
the effect of fixation or storage on the agarose gel, which
has been previously reported to decrease the staining in
IHC [20]. Thus, agarose gel samples were not suitable as
quality controls.
On the basis of the results of this study, we suggest
xenograft tumor samples as suitable additional quality
controls instead of cell line quality controls. Our obser-
vations indicate that xenograft tumor samples are similar
to patient tumor specimens, providing evidence that
they can be implemented for quality control. A previous
study, which applied xenograft tumor samples as the
quality control in the IHC assessment of estrogen
receptor (ER) and progesterone receptor (PR), reported
that the use of xenograft tumor samples as quality con-
trols provides advantages in relation to reproducibility of
biomarker, homogeneity of tissue histology, specimen
processing, availability, and cost compared with archived
tumor quality controls and cell line quality controls [21].
Similarly, our study confirmed that xenograft tumor
samples could be applied for quality control in the de-
tection of HER2 status. Furthermore, our study proved
that xenograft tumor quality controls could be applied
for the detection of both protein status (IHC) and gene
status (FISH). Regarding the economic factor, the cost of
producing xenograft tumor samples is similar to that in-
volved in producing cell line samples but lesser than that
involved in preparing clinical specimen tissue TMA or
FFPE-based quality controls (Table 1) [15].
Fig. 2 The results of HER2 gene amplification status evaluated by FISH assay. A-1 was section of cell lines sample without HER2 gene amplification
(MCF-7) while A-2 was that with positive HER2 gene amplification (SKBR-3). B-1 was section of agarose gel within cell lines sample without HER2
gene amplification (MCF-7) while A-2 was that with positive HER2 gene amplification (SKBR-3). C-1 was section of xenograft tumor sample
without HER2 gene amplification (MCF-7) while A-2 was that with positive HER2 gene amplification (SKBR-3). D-1 was section of clinical specimen
without HER2 gene amplification (A2) while A-2 was that with positive HER2 gene amplification (A12). The magnification was 1000 power
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However, some potential disadvantages need to be
considered. The characteristic features of cell lines for
establishing xenografts should be monitored during
long-term culture to ensure reliability. In theory, al-
though the target tumor cells in xenografts are human-
derived [22], they might contain vessels or fibrocytes
derived from mice. This indicates that the non-
specificity of the secondary antibody might lead to some
background staining in IHC. However, in our study, we
found that the influence of this background staining was
negligible. Nevertheless, poor tumorigenic potential and
slow growth of HER2-positive xenograft tumors might
impede its application [23]. In our study, we chose SCID
mice and Matrigel basement membrane matrix to im-
prove the tumorigenic potential [24]. Moreover, some
distinctions were found between the xenograft tumor
samples and clinical specimens in histological analysis.
In the clinical specimens, a larger number of normal
cells was observed and the tissue structure was more
complicated. Breast catheter, breast gland, and inflam-
matory cell infiltration was evident. In the xenograft
tumor samples, almost all the cells were tumor cells, and
the tissue structure was simple. As a result, the evalu-
ation of clinical specimens was more difficult than in the
case of xenograft tumor samples. Some performance
characteristics, especially the interpretation by observers
in the routine work, might be neglected to be evaluated
in EQA.
Conclusions
In this study, we compared three types of candidate refer-
ence samples with clinical specimens for quality control of
Fig. 3 The results of HER2 protein expression status evaluated by IHC assay. A-1 was section of cell lines sample without HER2 overexpression
(MCF-7) while A-2 was that with positive HER2 overexpression (SKBR-3). B-1 was section of agarose gel within cell lines sample without HER2
overexpression (MCF-7) while B-2 was that with positive HER2 overexpression (SKBR-3). C-1 was section of xenograft tumor sample without HER2
overexpression (MCF-7) while C-2 was that with positive HER2 overexpression (SKBR-3). D-1 was section of clinical specimen without HER2
overexpression (A2) while D-2 was that with positive HER2 overexpression (A12). The magnification was 400 power
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HER2 status detection. The study indicated that xenograft
tumor samples might be more suitable for FISH and IHC
as additional alternative quality controls than cell line
quality controls. However, xenograft tumor samples
cannot replace the traditional clinical specimen quality
controls until issues such as tumorigenic potential and
distinctions in histology are resolved.
Additional files
Additional file 1: The detailed results of HER2 gene amplification status
evaluated by FISH assay. A-1 to A-4 were section of cell lines samples
which were derived from MCF-7, MDA-MB-453, SKBR-3, BT474, respectively.
B-1 to B-4 were section of agarose gel within cell lines samples which were
derived from MCF-7, MDA-MB-453, SKBR-3, BT474, respectively. C-1 to C-4
were section of xenograft tumor samples which were derived from MCF-7,
MDA-MB-453, SKBR-3, BT474, respectively. The magnification was 1000
power. (PDF 17214 kb)
Additional file 2: The detailed results of HER2 protein expression status
evaluated by IHC assay. A-1 to A-4 were section of cell lines samples
which were derived from MCF-7, MDA-MB-453, SKBR-3, BT474, respectively.
B-1 to B-4 were section of agarose gel within cell lines samples which were
derived from MCF-7, MDA-MB-453, SKBR-3, BT474, respectively. C-1 to C-4
were section of xenograft tumor samples which were derived from MCF-7,
MDA-MB-453, SKBR-3, BT474, respectively. The magnification was 400 power.
(PDF 17387 kb)
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